Breaking News

Marken Establishes Orphan Drug Distribution Service

April 25, 2014

Offers delivery of clinical trial drugs to a patient's home or a remote clinic

Marken has developed a specialized distribution service for the orphan drug market for the delivery of clinical trial drugs directly to a patient's home or a remote clinic. The company also released a white paper for supply chain solutions for this growing market.
 
The production of orphan drugs, used to treat rare diseases, is increasing and will continue to rise with a compound annual growth rate of more than 7% per year between 2012 and 2018, according to the paper. Large pharma companies are investing in rare disease divisions and acquiring orphan drug assets, while small and mid-sized companies continue to expand their pipelines.
 
Development of these therapies through clinical trials involves small patient populations in many countries, often in remote areas. The paper states that approximately half of all orphan drugs are biologically derived and must be temperature controlled in order to ensure stability and efficacy throughout the trials, requiring special handling during transport to a clinic or a patient's home.  
 
"Marken recognized the pharma industry's increased focus on rare disease treatments and the complexity of safely transporting them to patients residing in multiple countries, each with its own unique customs and regulatory requirements," said Leslie Chaney Ph.D., Marken's global director of Preclinical and Direct to Patient Services and co-author of the white paper.
 
"Our Direct to Patient service utilizes Marken's team of experts in customs and trade compliance along with our extensive network of depot facilities and strategically located distribution centers throughout the world to provide timely global packaging, transport and tracking of orphan drug materials within regulatory, temperature and time constraints," she adds.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important